LAVA Therapeutics (LVTX)
(Delayed Data from NSDQ)
$1.59 USD
-0.06 (-3.64%)
Updated Oct 14, 2024 03:59 PM ET
After-Market: $1.59 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.59 USD
-0.06 (-3.64%)
Updated Oct 14, 2024 03:59 PM ET
After-Market: $1.59 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth B Momentum D VGM
Zacks News
Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 32.14% and 14.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
LAVA Therapeutics N.V. (LVTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
LAVA Therapeutics N.V. (LVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 7.69% and 7.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Why LAVA Therapeutics (LVTX) Might Surprise This Earnings Season
by Zacks Equity Research
LAVA Therapeutics (LVTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Nasdaq ETFs to Log Worst Month Since 2008? 5 Stocks Up 20%+
by Sanghamitra Saha
These top-ranked Nasdaq stocks returned more than 20% in January despite the index's downbeat performance.